Update on diagnostic practice: Tumors of the nervous system

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 7, 2009, Pages 1062-1077

  Pytel, Peter ^a   Lukas, Rimas V ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IRINOTECAN; ISOTRETINOIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMOZOLOMIDE; TUMOR MARKER;

ASTROCYTOMA; BRAIN BIOPSY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; CHROMOSOME 10; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ASSESSMENT; CYTOGENETICS; DOCTOR PATIENT RELATION; DRUG MECHANISM; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL SPECIALIST; MEDLINE; MEDULLOBLASTOMA; METASTASIS; MORPHOLOGY; NERVOUS SYSTEM TUMOR; NEUROECTODERM TUMOR; OLIGODENDROGLIOMA; PATHOLOGIST; PROGNOSIS; REVIEW; RHABDOID TUMOR; TERATOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MEDULLOBLASTOMA; NERVOUS SYSTEM NEOPLASMS; OLIGODENDROGLIOMA; RHABDOID TUMOR; WORLD HEALTH ORGANIZATION;

EID: 67649782160     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2007.
2. Aryan HE, Meltzer HS, Lu DC, Ozgur BM, Levy ML, Bruce DA. Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Childs Nerv Syst. 2005;21:477-481. (Pubitemid 40909186)
3. Hukin J, Siffert J, Cohen H, Velasquez L, Zagzag D, Allen J. Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro Oncol. 2003;5:188-196. (Pubitemid 36790348)
4. Lindsay A, Holthouse D, Robbins P, Knuckey N. Spinal leptomeningeal metastases following glioblastoma multiforme treated with radiotherapy. J Clin Neurosci. 2002;9:725-728. (Pubitemid 35364759)
5. Saito R, Kumabe T, Jokura H, Shirane R, Yoshimoto T. Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol. 2003;61:227-235. (Pubitemid 36342301)
6. Wagner S, Benesch M, Berthold F, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer. 2006;95:991-997. (Pubitemid 44606824)
7. Brat DJ, Scheithauer BW, Fuller GN, Tihan T. Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol. 2007; 17:319-324.
8. Fuller GN, Scheithauer BW. The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol. 2007;17:304-307.
9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
10. Roncaroli F, Scheithauer BW. Papillary tumor of the pineal region and spindle cell oncocytoma of the pituitary: new tumor entities in the 2007 WHO Classification. Brain Pathol. 2007;17:314-318. (Pubitemid 47000647)
11. Rosenblum MK. The 2007 WHO Classification of Nervous System Tumors: newly recognized members of the mixed glioneuronal group. Brain Pathol. 2007; 17:308-313.
12. Brat DJ, Parisi JE, Kleinschmidt-Demasters BK, et al. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med. 2008; 132:993-1007. (Pubitemid 351918708)
13. Templeton A, Hofer S, Topfer M, et al. Extraneural spread of glioblastoma- report of two cases. Onkologie. 2008;31:192-194. (Pubitemid 351700543)
14. Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation. 2003;76:340-343. (Pubitemid 36927995)
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
16. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8:189-193. (Pubitemid 46542664)
17. Puduvalli VK, Giglio P, Groves MD, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008;10:216-222.
18. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
19. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70:779-787.
20. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res. 1996;2: 1931-1935. (Pubitemid 27006624)
21. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999;1:44-51.
22. Tso CL, Freije WA, Day A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006;66:159-167. (Pubitemid 43166021)
23. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2003; 2:242-247.
24. Tso CL, Shintaku P, Chen J, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006;4:607-619. (Pubitemid 44497214)
25. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006;66: 11502-11513. (Pubitemid 46009984)
26. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173. (Pubitemid 43357943)
27. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol. 2000;156:425-432. (Pubitemid 30643797)
28. Peraud A,Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H. Genetic profile of the giant cell glioblastoma. Lab Invest. 1999;79:123-129. (Pubitemid 29110643)
29. Actor B, Cobbers JM, Buschges R, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer. 2002;34:416-427. (Pubitemid 34787463)
30. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol. 2008; 67:1-15.
31. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007;13: 378-381. (Pubitemid 46225339)
32. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353: 2012-2024. (Pubitemid 41609094)
33. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501. (Pubitemid 37328931)
34. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005;11:7841-7850. (Pubitemid 41611629)
35. Preusser M, Gelpi E, Rottenfusser A, et al. Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. J Neurooncol. 2008;89(2):211-218.
36. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880-887. (Pubitemid 41417939)
37. Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTENdeficient and PTEN-intact glioblastoma cells. Cancer Res. 2006;66:7864-7869. (Pubitemid 44299148)
38. Juillerat A, Juillerat-Jeanneret L. S-alkylthiolation of O6-methylguanine- DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy. Expert Opin Ther Targets. 2007;11:349-361. (Pubitemid 46290958)
39. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
40. Preusser M, Janzer RC, Felsberg J, et al. Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18(4):520-532.
41. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-537. (Pubitemid 39031388)
42. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453-461. (Pubitemid 351597795)
43. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113(2):405-410.
44. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-83. (Pubitemid 46252277)
45. Mathews MS, Linskey ME, Hasso AN, Fruehauf JP. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol. 2008;70(6): 649-652.
46. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008;88:339-347.
47. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
48. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67:323-326. (Pubitemid 46108339)
49. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11: 165-180. (Pubitemid 43261763)
50. Cheng Y, Pang JC, Ng HK, et al. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology. 2000;37:437-444. (Pubitemid 30846392)
51. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001;61:6885-6891. (Pubitemid 32896514)
52. Addo-Yobo SO, Straessle J, Anwar A, Donson AM, Kleinschmidt-Demasters BK, Foreman NK. Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2006;65:769-775. (Pubitemid 44200317)
53. Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000;89:1569-1576. (Pubitemid 30727225)
54. Perry A. Pathology of low-grade gliomas: an update of emerging concepts. Neuro Oncol. 2003;5:168-178. (Pubitemid 36790346)
55. Nakamura M, Ishii K, Watanabe K, et al. Surgical treatment of intramedullary spinal cord tumors: prognosis and complications. Spinal Cord. 2008;46: 282-286.
56. Nishio S, Morioka T, Fujii K, Inamura T, Fukui M. Spinal cord gliomas: management and outcome with reference to adjuvant therapy. J Clin Neurosci. 2000;7:20-23. (Pubitemid 30484596)
57. Bailey P, Bucy PC. Oligodendrogliomas of the brain. J Pathol Bacteriol. 1929;32:735-751.
58. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. (Pubitemid 39551674)
59. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol. 2002;61:947-955. (Pubitemid 35278716)
60. Plesec TP, Prayson RA. Frozen section discrepancy in the evaluation of central nervous system tumors. Arch Pathol Lab Med. 2007;131:1532-1540. (Pubitemid 47606719)
61. Bruner JM. Oligodendroglioma: diagnosis and prognosis. Semin Diagn Pathol. 1987;4:251-261. (Pubitemid 18140835)
62. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 1999;45: 1279-1291.
63. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79:1381-1393. (Pubitemid 27143246)
64. Perry A. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol. 2001;8:183-199.
65. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery. 1997;41:878-884. (Pubitemid 27422116)
66. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer. 1996;78: 1107-1113. (Pubitemid 26284877)
67. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE. Clinicopathologic correlations in the oligodendroglioma. Cancer. 1987;59:1345-1352.
68. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW. Grading of oligodendrogliomas. Cancer. 1983;52:2107-2114. (Pubitemid 14232255)
69. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol. 1986;45:65-78. (Pubitemid 16189844)
70. Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol. 2006;24:5419-5426. (Pubitemid 46623175)
71. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360-369. (Pubitemid 351782844)
72. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545-551. (Pubitemid 46869696)
73. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10; p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006;65:988-994. (Pubitemid 44521799)
74. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861. (Pubitemid 44672036)
75. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res. 2005;11:1119-1128. (Pubitemid 40175761)
76. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 2004;14:121-130. (Pubitemid 38656383)
77. Tews B, Felsberg J, Hartmann C, et al. Identification of novel oligodendroglioma- associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer. 2006;119:792-800. (Pubitemid 44051441)
78. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479. (Pubitemid 28482012)
79. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003;97:1276-1284. (Pubitemid 36237315)
80. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131:242-251. (Pubitemid 46255646)
81. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645. (Pubitemid 30078545)
82. Iwamoto FM, Nicolardi L, Demopoulos A, et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 2008;88:293-298.
83. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714. (Pubitemid 46630566)
84. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722. (Pubitemid 46630567)
85. Fortin D, Macdonald DR, Stitt L, Cairncross JG. PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci. 2001;28:215-223. (Pubitemid 32785925)
86. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 2003;61:267-273. (Pubitemid 36342306)
87. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42:2499-2503. (Pubitemid 44468379)
88. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836. (Pubitemid 46791397)
89. Brada M, Ashley S, Dowe A, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol. 2005;16:942-949. (Pubitemid 40903921)
90. Weller M, Berger H, Hartmann C, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res. 2007; 13:6933-6937. (Pubitemid 350276872)
91. Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, Laws ER Jr,Vedrenne C. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery. 1988;23:545-556. (Pubitemid 18268160)
92. Hirose T, Scheithauer BW, Lopes MB, Gerber HA, Altermatt HJ, VandenBerg SR. Ganglioglioma: an ultrastructural and immunohistochemical study. Cancer. 1997;79:989-1003.
93. Wolf HK, Muller MB, Spanle M, Zentner J, Schramm J,Wiestler OD. Ganglioglioma: a detailed histopathological and immunohistochemical analysis of 61 cases. Acta Neuropathol. 1994;88:166-173. (Pubitemid 24233248)
94. VandenBerg SR, May EE, Rubinstein LJ, et al. Desmoplastic supratentorial neuroepithelial tumors of infancy with divergent differentiation potential ("desmoplastic infantile gangliogliomas"). Report on 11 cases of a distinctive embryonal tumor with favorable prognosis. J Neurosurg. 1987;66:58-71. (Pubitemid 17214283)
95. Edgar MA, Rosenblum MK. Mixed glioneuronal tumors: recently described entities. Arch Pathol Lab Med. 2007;131:228-233. (Pubitemid 46255644)
96. Komori T, Scheithauer BW, Hirose T. A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol. 2002;26:582-591. (Pubitemid 34438718)
97. Komori T, Scheithauer BW, Anthony DC, et al. Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol. 1998; 22:1171-1183. (Pubitemid 28462765)
98. Teo JG, Gultekin SH, Bilsky M, Gutin P, Rosenblum MK. A distinctive glioneuronal tumor of the adult cerebrum with neuropil-like (including "rosetted") islands: report of 4 cases. Am J Surg Pathol. 1999;23:502-510. (Pubitemid 29214951)
99. Barbashina V, Salazar P, Ladanyi M, Rosenblum MK, Edgar MA. Glioneuronal tumor with neuropil-like islands (GTNI): a report of 8 cases with chromosome 1p/19q deletion analysis. Am J Surg Pathol. 2007;31:1196-1202. (Pubitemid 47207123)
100. Sasaki A, Hirato J, Nakazato Y, Tamura M, Kadowaki H. Recurrent anaplastic ganglioglioma: pathological characterization of tumor cells. Case report. J Neurosurg. 1996;84:1055-1059. (Pubitemid 26159125)
101. Mittler MA, Walters BC, Fried AH, Sotomayor EA, Stopa EG. Malignant glial tumor arising from the site of a previous hamartoma/ganglioglioma: coincidence or malignant transformation? Pediatr Neurosurg. 1999;30:132-134. (Pubitemid 29258726)
102. Johnson MD, Jennings MT, Toms ST. Oligodendroglial ganglioglioma with anaplastic features arising from the thalamus. Pediatr Neurosurg. 2001;34:301-305. (Pubitemid 32656684)
103. Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer. 2004;101:146-155. (Pubitemid 38812434)
104. Rushing EJ, Thompson LD, Mena H. Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. Ann Diagn Pathol. 2003;7:240-244. (Pubitemid 36999492)
105. Jay V, Squire J, Becker LE, Humphreys R. Malignant transformation in a ganglioglioma with anaplastic neuronal and astrocytic components. Report of a case with flow cytometric and cytogenetic analysis. Cancer. 1994;73:2862-2868. (Pubitemid 24166278)
106. Tarnaris A, O'Brien C, Redfern RM. Ganglioglioma with anaplastic recurrence of the neuronal element following radiotherapy. Clin Neurol Neurosurg. 2006;108:761-767. (Pubitemid 44709773)
107. Mittelbronn M, Schittenhelm J, Lemke D, et al. Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components. Neuropathology. 2007;27:463-467. (Pubitemid 47459712)
108. Craver RD, Nadell J, Nelson JS. Desmoplastic infantile ganglioglioma. Pediatr Dev Pathol. 1999;2:582-587. (Pubitemid 29498465)
109. Lonnrot K, Terho M, Kahara V, Haapasalo H, Helen P. Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol. 2007;68:304-308. (Pubitemid 47284374)
110. Hoving EW, Kros JM, Groninger E, den Dunnen WF. Desmoplastic infantile ganglioglioma with a malignant course. J Neurosurg Pediatrics. 2008;1:95-98.
111. Vyberg M, Ulhoi BP, Teglbjaerg PS. Neuronal features of oligodendrogliomas- an ultrastructural and immunohistochemical study. Histopathology. 2007; 50:887-896. (Pubitemid 46850061)
112. Wharton SB, Chan KK, Hamilton FA, Anderson JR. Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study. Neuropathol Appl Neurobiol. 1998;24:302-308. (Pubitemid 28389127)
113. Rodriguez FJ, Scheithauer BW, Robbins PD, et al. Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol. 2007;113:313-324. (Pubitemid 46443566)
114. Kordek R, Biernat W, Sapieja W, Alwasiak J, Liberski PP. Pleomorphic xanthoastrocytoma with a gangliomatous component: an immunohistochemical and ultrastructural study. Acta Neuropathol. 1995;89:194-197.
115. Powell SZ, Yachnis AT, Rorke LB, Rojiani AM, Eskin TA. Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors. Am J Surg Pathol. 1996;20:80-85. (Pubitemid 26007713)
116. Perry A, Miller CR, Gujrati M, et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol. 2009;19(1):81-90.
117. Shibahara J, Fukayama M. Secondary glioblastoma with advanced neuronal immunophenotype. Virchows Arch. 2005;447:665-668. (Pubitemid 41291641)
118. Vogel H, Fuller GN. Primitive neuroectodermal tumors, embryonal tumors, and other small cell and poorly differentiated malignant neoplasms of the central and peripheral nervous systems. Ann Diagn Pathol. 2003;7:387-398. (Pubitemid 38017996)
119. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol. 2008;3:341-365.
120. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436-442. (Pubitemid 34100955)
121. Inda MM, Mercapide J, Munoz J, et al. PTEN and DMBT1 homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. Oncol Rep. 2004;12:1341-1347.
122. Brat DJ, Shehata BM, Castellano-Sanchez AA, et al. Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol. 2007;17:276-281. (Pubitemid 47000636)
123. Pytel P. Spectrum of pediatric gliomas: implications for the development of future therapies. Expert Rev Anticancer Ther. 2007;7:S51-S60.
124. Fisher PG, Burger PC, Eberhart CG. Biologic risk stratification of medulloblastoma: the real time is now. J Clin Oncol. 2004;22:971-974. (Pubitemid 41095025)
125. Ullrich NJ, Pomeroy SL. Pediatric brain tumors. Neurol Clin. 2003;21: 897-913. (Pubitemid 37267796)
126. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004;22:994-998. (Pubitemid 41095030)
127. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22:984-993. (Pubitemid 41095029)
128. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002;94:552-560. (Pubitemid 34081387)
129. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63:441-449. (Pubitemid 38669665)
130. Biegel JA, Rorke LB, Emanuel BS. Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med. 1989;321:906. (Pubitemid 19238630)
131. Biegel JA, Rorke LB, Packer RJ, Emanuel BS. Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg. 1990;73:710-714. (Pubitemid 20364485)
132. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998;22:1083-1092. (Pubitemid 28411066)
133. Bhattacharjee M, Hicks J, Langford L, et al. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol. 1997; 21:369-378. (Pubitemid 27276053)
134. Biegel JA, Fogelgren B, Zhou JY, et al. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res. 2000;6:2759-2763. (Pubitemid 30482115)
135. Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004;28: 644-650. (Pubitemid 38579568)
136. Strother D. Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther. 2005;5:907-915. (Pubitemid 41599964)
137. Kazmi SA, Perry A, Pressey JG, Wellons JC, Hammers Y, Palmer CA. Primary Ewing sarcoma of the brain: a case report and literature review. Diagn Mol Pathol. 2007;16:108-111. (Pubitemid 47164744)
138. Mobley BC, Roulston D, Shah GV, Bijwaard KE, McKeever PE. Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review. Hum Pathol. 2006;37:845-853. (Pubitemid 43902944)
139. Kampman WA, Kros JM, De Jong TH, Lequin MH. Primitive neuroectodermal tumours (PNETs) located in the spinal canal; the relevance of classification as central or peripheral PNET: case report of a primary spinal PNET occurrence with a critical literature review. J Neurooncol. 2006;77:65-72. (Pubitemid 43870563)